capecitabine has been researched along with Carcinoma, Ductal, Pancreatic in 28 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (3.57) | 29.6817 |
| 2010's | 19 (67.86) | 24.3611 |
| 2020's | 8 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Besselink, MG; Bonsing, BA; Bouwense, SAW; de Jong, EJM; de Meijer, VE; de Vos-Geelen, J; Geurts, SME; Homs, MYV; Janssen, QP; Koerkamp, BG; Simons, TFA; Tjan-Heijnen, VCG; Valkenburg-van Iersel, LBJ; van der Geest, LG; van Laarhoven, HWM; Wilmink, JW | 1 |
| Aliru, M; Bagereka, P; Bhosale, P; Crane, CH; Das, P; Holliday, EB; Ikoma, N; Jacobson, G; Javle, M; Katz, MH; Kim, M; Koay, EJ; Koong, AC; Krishnan, S; Lee, JE; Ludmir, EB; Minsky, BD; Overman, M; Pant, S; Rodriguez, MJ; Smith, GL; Tamm, E; Taniguchi, CM; Tzeng, CW; Van Wieren, A; Varadhachary, G; Wang, H; Wang, X; Wolff, RA; Zaid, M | 1 |
| Agarwal, P; Bever, K; Christenson, ES; De Jesus-Acosta, A; Durham, J; Laheru, D; Le, DT; Lim, SJ; Ryan, A; Scharpf, RB; Wang, H | 1 |
| Baker, KK; Chiorean, EG; Coveler, AL; Hannan, LM; King, GG; Koh, WJ; Mann, GN; Park, JO; Pillarisetty, VG; Redman, MW; Sham, JG; Swanson, PE; Whiting, SH; Zhen, DB | 1 |
| Anthoney, A; Borg, D; Büchler, MW; Campbell, F; Crosby, T; Cummins, S; Cunningham, D; Darby, S; Falk, S; Faluyi, O; Ghaneh, P; Gillmore, R; Glimelius, B; Hackert, T; Halloran, CM; Hammel, P; Izbicki, JR; Jackson, R; Jones, RP; Lerch, MM; Lind, P; Mayerle, J; McDonald, A; Meyer, T; Middleton, GW; Neoptolemos, JP; O'Reilly, DA; Palmer, DH; Patel, K; Psarelli, EE; Ross, PJ; Sherriff, D; Soomal, R; Sothi, S; Strobel, O; Ting, Y; Tjaden, C; Valle, JW; Wadsley, J; Wasan, H | 1 |
| Abu Hilal, M; Alseidi, A; Bassi, C; Besselink, MG; Bolm, L; Busch, OR; De Pastena, M; Del Chiaro, M; Gill, AJ; Groen, JV; Groot Koerkamp, B; Groot, VP; Halimi, A; He, J; Jang, JY; Keck, T; Malleo, G; Marchegiani, G; Mieog, JS; Mittal, A; Samra, JS; Steyerberg, EW; Strijker, M; Suhool, A; van Eijck, CH; van Roessel, S; Wolfgang, CL; Zarantonello, L | 1 |
| Fanchon, LM; Gangangari, K; Humm, JL; O'Donoghue, I; Pillarsetty, N; Russell, J; Yu, KH | 1 |
| Bachet, JB; Mas, L; Schwarz, L | 1 |
| Custodio, A; Feliu, J; Garcia-Cuesta, JA; Ghanem, I; Gutierrez-Sainz, L; Martinez-Perez, D; Villamayor, J; Viñal, D | 1 |
| Bianconi, D; Gleiss, A; Heller, G; Herac, M; Kieler, M; Liebmann-Reindl, S; Prager, GW; Scheithauer, W; Spies, D; Streubel, B; Unseld, M; Zielinski, CC | 1 |
| Arena, J; Bergamin, S; Chua, TC; Clarke, S; Diakos, C; Gibbs, E; Gill, AJ; Hruby, G; Itchins, M; Kim, S; Kneebone, A; Maher, R; Mittal, A; Nahm, CB; Pavlakis, N; Rabindran, J; Samra, J; Wong, M | 1 |
| Arcidiacono, PG; Balzano, G; Castoldi, R; Ceraulo, D; Chiaravalli, M; Doglioni, C; Falconi, M; Fugazza, C; Gianni, L; Macchini, M; Nicoletti, R; Partelli, S; Passoni, P; Peretti, U; Pircher, C; Reni, M; Zanon, S | 1 |
| Blackford, AL; Cameron, JL; Choti, MA; De Jesus-Acosta, A; Donehower, RC; Edil, BH; Ellsworth, S; Fan, KY; Hacker-Prietz, A; Herman, JM; Hidalgo, M; Hruban, RH; Laheru, DA; Le, DT; Pawlik, TM; Schulick, RD; Wild, AT; Wolfgang, CL; Wood, LD; Zheng, L | 1 |
| Bapiro, TE; Bramhall, JL; Cook, N; Courtin, A; Jodrell, DI; Krippendorff, BF; Neesse, A; Richards, FM; Tuveson, DA | 1 |
| Adams, J; Allen, JN; Ancukiewicz, M; Blaszkowsky, LS; Borger, DR; Boucher, Y; Clark, JW; DeLaney, TF; Deshpande, V; Duda, DG; Fernandez-del Castillo, C; Ferrone, CR; Grillo, T; Hong, TS; Jain, RK; Kwak, EL; Mamon, HJ; Ryan, DP; Shinagare, S; Wadlow, RC; Winrich, B; Wo, JY; Yeap, BY; Zhu, AX | 1 |
| Bergmann, F; Büchler, MW; Combs, SE; Debus, J; Habermehl, D; Jäger, D; Kessel, KA; Naumann, P; Werner, J | 1 |
| Bitzer, M; Maier-Stocker, C; Malek, NP; Plentz, RR | 1 |
| Kim, YT; Lee, SH; Paik, WH; Park, JM; Ryu, JK; Song, BJ | 1 |
| Barton, S; Begum, R; Braconi, C; Chau, I; Cunningham, D; Fassan, M; Guzzardo, V; Hawkins, M; Khan, K; Oates, J; Peckitt, C; Rao, S; Starling, N; Tait, D; Thomas, J; Watkins, D | 1 |
| Costello, E; Cox, T; Ghaneh, P; Greenhalf, W; Middleton, G; Neoptolemos, JP; Palmer, DH; Shaw, V | 1 |
| Ahmad, SA; Bekaii-Saab, T; Cardin, D; Collisson, E; Conway, W; Frankel, W; Herman, JM; Hoffman, JP; Katz, MH; Kindler, H; LoConte, N; Lowy, AM; Marsh, Rde W; Martin, R; Philip, P; Schwartz, L; Shen, P; Shi, Q; Talamonti, M; Truty, M; Venook, AP | 1 |
| Bria, E; Carlini, P; Carpanese, L; Cognetti, F; De Marco, S; Gelibter, A; Milella, M; Nuzzo, C; Pino, MS; Ruggeri, EM; Sperduti, I | 1 |
| Greten, TF; Manns, MP; Plentz, RR | 1 |
| Adams, J; Blaszkowsky, LS; DeLaney, TF; Fernandez-Del Castillo, C; Hong, TS; Kwak, EL; Mamon, HJ; Mino-Kenudson, M; Ryan, DP; Winrich, B; Yeap, B | 1 |
| Cameron, JL; Herman, JM; Horowitz, DP; Hsu, CC; Makary, MA; Pawlik, TM; Robinson, R; Schulick, RD; Wang, J; Winter, JM | 1 |
| Adams, RB; Bauer, TW; de Lange, EE; Nolan, NJ; Rich, TA; Stelow, EB; Stokes, JB; Walters, DM; Weiss, GR | 1 |
| Adenis, A; Conroy, T; Gavoille, C | 1 |
| Choi, DW; Choi, SH; Heo, JS; Jang, KT; Kang, WK; Kim, ST; Lee, J; Lee, JK; Lee, KH; Lee, KT; Lim, DH; Lim, HY; Park, HC; Park, JO; Park, SH; Park, YS | 1 |
3 review(s) available for capecitabine and Carcinoma, Ductal, Pancreatic
| Article | Year |
|---|---|
Adjuvant chemotherapy in pancreatic cancer: state of the art and future perspectives.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Oxaliplatin; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2020 |
Molecular therapy of pancreatic cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Benzenesulfonates; Bevacizumab; Capecitabine; Carcinoma, Pancreatic Ductal; Cetuximab; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Imidazoles; Indazoles; Neoplasm Invasiveness; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Phthalazines; Prognosis; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Risk Assessment; Sorafenib; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor A | 2010 |
Metastatic pancreatic cancer: old drugs, new paradigms.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Clinical Trials, Phase III as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Heparin; Humans; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Platinum; Quinazolines | 2011 |
11 trial(s) available for capecitabine and Carcinoma, Ductal, Pancreatic
| Article | Year |
|---|---|
Nab-Paclitaxel, Capecitabine, and Radiation Therapy After Induction Chemotherapy in Treating Patients With Locally Advanced and Borderline Resectable Pancreatic Cancer: Phase 1 Trial and Imaging-based Biomarker Validation.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Capecitabine; Carcinoma, Pancreatic Ductal; Deoxycytidine; Humans; Induction Chemotherapy; Paclitaxel; Pancreatic Neoplasms | 2022 |
Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Prospective Studies; Treatment Outcome | 2019 |
A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma.
Topics: Adolescent; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Italy; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Progression-Free Survival; Time Factors; Young Adult | 2018 |
Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Deoxycytidine; Dose Fractionation, Radiation; Drug Eruptions; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Quality of Life; Quinazolines; Radiotherapy, Intensity-Modulated | 2013 |
A phase 1/2 and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine followed by early surgery for resectable pancreatic ductal adenocarcinoma.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; CA-19-9 Antigen; Capecitabine; Carcinoembryonic Antigen; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Genes, ras; Hepatocyte Growth Factor; Humans; Male; Middle Aged; Pancreatic Neoplasms; Pancreaticoduodenectomy; Prognosis; Prospective Studies; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Proton Therapy; ras Proteins; Receptors, CXCR | 2014 |
miR-21 expression and clinical outcome in locally advanced pancreatic cancer: exploratory analysis of the pancreatic cancer Erbitux, radiotherapy and UFT (PERU) trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Carcinoma, Pancreatic Ductal; Cetuximab; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Male; MicroRNAs; Middle Aged; Pancreatic Neoplasms; Tegafur; Uracil | 2016 |
Immunobiological effects of gemcitabine and capecitabine combination chemotherapy in advanced pancreatic ductal adenocarcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; C-Reactive Protein; CA-19-9 Antigen; Cancer Vaccines; Capecitabine; Carcinoma, Pancreatic Ductal; Cell Proliferation; Deoxycytidine; Female; Gemcitabine; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Hypersensitivity, Delayed; Interleukin-6; Male; Middle Aged; Pancreatic Neoplasms; Peptide Fragments; T-Lymphocytes; Telomerase | 2016 |
Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Feasibility Studies; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Margins of Excision; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Pilot Projects; Prospective Studies; Radiotherapy, Intensity-Modulated; Survival Rate | 2016 |
Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Carcinoma, Pancreatic Ductal; Celecoxib; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Pyrazoles; Sulfonamides | 2009 |
Phase I study of preoperative short-course chemoradiation with proton beam therapy and capecitabine for resectable pancreatic ductal adenocarcinoma of the head.
Topics: Aged; Aged, 80 and over; Capecitabine; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Cytarabine; Deoxycytidine; Feasibility Studies; Female; Fluorouracil; Humans; Length of Stay; Male; Middle Aged; Pancreatic Neoplasms; Pancreaticoduodenectomy; Prescriptions; Prospective Studies; Proton Therapy; Radiography; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted | 2011 |
Safety and efficacy of adjuvant chemoradiation therapy with capecitabine after resection of pancreatic ductal adenocarcinoma: a retrospective review.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Pancreaticoduodenectomy; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate; Treatment Outcome | 2012 |
14 other study(ies) available for capecitabine and Carcinoma, Ductal, Pancreatic
| Article | Year |
|---|---|
Real-world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms | 2022 |
Cell-free DNA Predicts Prolonged Response to Multi-agent Chemotherapy in Pancreatic Ductal Adenocarcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Capecitabine; Carcinoma, Pancreatic Ductal; Cell-Free Nucleic Acids; Cisplatin; Deoxycytidine; Humans; Irinotecan; Pancreatic Neoplasms; Pilot Projects; Proto-Oncogene Proteins p21(ras) | 2022 |
Perioperative Chemotherapy and Chemoradiotherapy for Patients With Resectable and Borderline Resectable Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Fluorouracil; Humans; Neoadjuvant Therapy; Oxaliplatin; Pancreatic Neoplasms | 2023 |
International validation and update of the Amsterdam model for prediction of survival after pancreatoduodenectomy for pancreatic cancer.
Topics: Aged; Antineoplastic Agents; Area Under Curve; Capecitabine; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Clinical Decision Rules; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Internationality; Lymph Nodes; Male; Margins of Excision; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Staging; Pancreatic Neoplasms; Pancreaticoduodenectomy; Radiotherapy; Reproducibility of Results; Retrospective Studies | 2020 |
Comparing the intra-tumoral distribution of Gemcitabine, 5-Fluorouracil, and Capecitabine in a murine model of pancreatic ductal adenocarcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Pancreatic Ductal; Cell Hypoxia; Deoxycytidine; Diagnostic Techniques, Radioisotope; Disease Models, Animal; Fluorouracil; Gemcitabine; Mice; Mice, Inbred C57BL; Organoids; Pancreatic Neoplasms | 2020 |
Prognostic factors in advanced pancreatic ductal adenocarcinoma patients-receiving second-line treatment: a single institution experience.
Topics: Adult; Aged; Aged, 80 and over; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Clinical Decision-Making; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Logistic Models; Lymphocytes; Male; Middle Aged; Neutrophils; Oxaliplatin; Oxaloacetates; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Time Factors | 2021 |
Biochemical and genetic predictors of overall survival in patients with metastatic pancreatic cancer treated with capecitabine and nab-paclitaxel.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Blood Chemical Analysis; Capecitabine; Carcinoma, Pancreatic Ductal; Clinical Trials, Phase II as Topic; Female; Gene Expression Profiling; Humans; Male; Middle Aged; Paclitaxel; Pancreas; Prognosis; Retrospective Studies; Sequence Analysis, RNA; Serpins; Survival Analysis; Treatment Outcome | 2017 |
Retrospective cohort analysis of neoadjuvant treatment and survival in resectable and borderline resectable pancreatic ductal adenocarcinoma in a high volume referral centre.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Hospitals, High-Volume; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Paclitaxel; Pancreatic Neoplasms; Positron-Emission Tomography; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Survival Rate | 2017 |
Anti-tumour efficacy of capecitabine in a genetically engineered mouse model of pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cytidine Deaminase; Deoxycytidine; Disease Models, Animal; Drug Screening Assays, Antitumor; Fluorouracil; Gemcitabine; Mice; Mice, Transgenic; Neoplasm Transplantation; Pancreatic Neoplasms; Prodrugs; Tissue Distribution | 2013 |
Prognostic impact of CA 19-9 on outcome after neoadjuvant chemoradiation in patients with locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Capecitabine; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Survival Rate | 2014 |
Analysis of second-line chemotherapies for ductal pancreatic adenocarcinoma in a German single-center cohort.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaloacetates; Palliative Care; Pancreatic Neoplasms; Quinazolines; Retrospective Studies; Survival Analysis; Treatment Outcome | 2014 |
Objective Assessment of Surgical Restaging after Concurrent Chemoradiation for Locally Advanced Pancreatic Cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pancreas; Pancreatic Neoplasms; Radiography; Retrospective Studies; Treatment Outcome | 2015 |
Adjuvant chemoradiation therapy after pancreaticoduodenectomy in elderly patients with pancreatic adenocarcinoma.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Humans; Lymphatic Metastasis; Male; Middle Aged; Pancreatic Neoplasms; Pancreaticoduodenectomy; Postoperative Care; Proportional Hazards Models; Radiotherapy, Adjuvant; Survival Analysis | 2011 |
Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pancreatectomy; Pancreatic Neoplasms; Preoperative Care; Prospective Studies; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate; Treatment Outcome | 2011 |